Earendil Labs closed a $787 million financing to accelerate a broad pipeline of AI-designed biologics, the company said. The round included venture investors Dimension and Luminous Ventures plus Sanofi as a strategic partner; proceeds will fund multiple programs toward clinical testing and expansion of R&D capacity across the U.S. and China. Earendil claims an AI platform that has produced over 40 programs, with at least one program positioned for Phase 2. CEO Jian Peng said the funding permits operating “at a fundamentally different scale,” underlining the firm’s intent to pursue parallel clinical development and to build a larger discovery-to-clinic organization.